Persistent Asset Partners Ltd Makes New $4.57 Million Investment in BioMarin Pharmaceutical Inc. $BMRN

Key Points

• Persistent Asset Partners purchased 79,933 BioMarin shares worth approximately $4.57 million during the second quarter, making BMRN 1.4% of its portfolio and its 15th-largest holding.
• BioMarin reported quarterly EPS of $1.20, exceeding the $0.95 consensus estimate, while revenue rose 20% year over year to $989.71 million. The company issued fiscal 2026 EPS guidance of $4.90–$5.10.
• Analyst sentiment remains positive, with an average “Moderate Buy” rating and an $88 price target, although ratings range from “Strong Buy” to “Sell.” Institutional investors collectively own 98.71% of BMRN shares.

Persistent Asset Partners Ltd purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 79,933 shares of the biotechnology company's stock, valued at approximately $4,574,000. BioMarin Pharmaceutical accounts for 1.4% of Persistent Asset Partners Ltd's investment portfolio, making the stock its 15th biggest holding.

A number of other institutional investors also recently added to or reduced their stakes in BMRN. Viking Global Investors LP boosted its holdings in shares of BioMarin Pharmaceutical by 13.8% in the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company's stock valued at $675,505,000 after acquiring an additional 1,488,552 shares in the last quarter. Norges Bank acquired a new position in BioMarin Pharmaceutical during the fourth quarter worth about $447,572,000. AQR Capital Management LLC raised its position in BioMarin Pharmaceutical by 12.7% in the fourth quarter. AQR Capital Management LLC now owns 6,686,916 shares of the biotechnology company's stock worth $395,197,000 after acquiring an additional 754,807 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in BioMarin Pharmaceutical by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company's stock valued at $214,804,000 after acquiring an additional 481,176 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of BioMarin Pharmaceutical by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 3,674,089 shares of the biotechnology company's stock valued at $218,395,000 after purchasing an additional 131,969 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Price Performance

Shares of BMRN stock opened at $67.36 on Monday. BioMarin Pharmaceutical Inc. has a 12 month low of $49.26 and a 12 month high of $70.98. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The firm has a market cap of $13.04 billion, a PE ratio of 182.05, a price-to-earnings-growth ratio of 0.47 and a beta of 0.24. The stock has a 50 day moving average of $59.56 and a 200-day moving average of $57.51.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.25. The business had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. BioMarin Pharmaceutical's quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter last year, the company posted $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, equities analysts predict that BioMarin Pharmaceutical Inc. will post 4.22 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on BMRN shares. Citigroup raised their target price on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a report on Thursday, July 16th. Canaccord Genuity Group raised their target price on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Morgan Stanley boosted their price target on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an "overweight" rating in a report on Friday, August 7th. UBS Group reaffirmed a "neutral" rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Finally, Weiss Ratings downgraded shares of BioMarin Pharmaceutical from a "hold (c-)" rating to a "sell (d)" rating in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical has an average rating of "Moderate Buy" and an average target price of $88.00.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source